Top

Published in:

Open Access 01-12-2015 | Commentary

Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?

Author: Neville D Yeomans

Published in: BMC Medicine | Issue 1/2015

Abstract

In a recently published article in BMC Medicine, Scarpignato and colleagues present the results of a consensus conference that addressed several aspects of the management of pain in patients with osteoarthritis. The main areas covered include the relative safety in regard to gastrointestinal and cardiovascular adverse events of non-selective ‘traditional’ non-steroidal anti-inflammatory drugs (NSAIDs) versus cyclooxygenase-2 selective NSAIDs. The role of co-therapy with proton pump inhibitors in enhancing gastrointestinal safety is also reviewed.

This commentary focuses on two areas that the consensus conference addressed, i) the whole length of gastrointestinal tract risk profile of the various NSAIDs (not just the ulcer risks in stomach and duodenum); ii) more recent information, but still some uncertainties, about the cardiovascular risks associated with the two classes of NSAID in general, and naproxen in particular.

Please see related article: http://dx.doi.org/10.1186/s12916-015-0285-8

Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD004257.PubMed

Hernandez-Diaz S, Rodriguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med. 2000;160:2093–9.CrossRefPubMed

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971;231:232–5.CrossRefPubMed

Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;3:73.CrossRef

Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28.CrossRefPubMed

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.CrossRefPubMed

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028–35.CrossRefPubMed

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102.CrossRefPubMed

European Medicines Agency concludes action on COX-2 inhibitors. 2005. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/01/news_detail_000969.jsp&mid=WC0b01ac058004d5c1.

10.

Jenkins JK, Seligman PJ. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. April 6, 2005. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106201.pdf.

11.

FDA, Transcript for the February 11, 2014 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee. 2014. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM398864.pdf

12.

Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt R; for International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis: an expert consensus addressing benefits and gastrointestinal as well as cardiovascular risks. BMC Med. 2015;13.

13.

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–42.CrossRefPubMed

14.

Bhatt DL, Scheiman J, Abraham NS, Antman EN, Chan FKL, Ferburg KD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J Amer Coll Cardiol. 2008;52:1502–7.CrossRef

15.

Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103:2908–18.CrossRefPubMed

16.

Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–96.CrossRefPubMed

17.

Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–94.CrossRefPubMed

18.

Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35:209–19.CrossRefPubMed

19.

Runkel R, Chaplin M, Boost G, Segre E, Forchielli E. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharmaceut Sci. 1972;61:703–8.CrossRef

20.

Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol. 1984;33:155–9.CrossRefPubMed

21.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.CrossRef

22.

Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Lüscher TF, et al. Rationale, design, and governance of prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (PRECISION), a cardiovascular endpoint trial of non-steroidal anti-inflammatory agents in patients with arthritis. Am Heart J. 2009;157:606–12.CrossRefPubMed

23.

FDA, Center for Drug Evaluation and Research. Summary minutes of the joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, February 10–11, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM395527.pdf.

Title: Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
Author: Neville D Yeomans
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2015
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-015-0291-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Repeat HIV-testing is associated with an increase in behavioral risk among men who have sex with men: a cohort study

Potential for international spread of wild poliovirus via travelers

Implementing supported self-management for asthma: a systematic review and suggested hierarchy of evidence of implementation studies

The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study

Idiopathic pulmonary fibrosis: moving forward

Targeting and limiting surgery for patients with node-positive breast cancer